Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
MWN-AI** Summary
Dyadic International, Inc. ("Dyadic"), a biotechnology company specializing in the scalable production of high-value functional input proteins, announced it will report its full-year financial results for 2025 on March 25, 2026. The report will detail the company's financial performance for the year ending December 31, 2025, and will be followed by a corporate update conference call scheduled for 5:00 p.m. Eastern Time.
Dyadic utilizes proprietary gene expression platforms, including its C1 and Dapibus™ expression systems, to produce recombinant proteins aimed at enhancing efficiency and sustainability in life sciences, food and nutrition, and industrial biotech applications. Dyadic’s business model involves licensing these proteins to partners in various markets, fostering continued growth and innovation.
Investors and analysts can participate in the conference call by dialing +1-877-407-9219 or +1-412-652-1274, with the conference ID 13758915. A webcast of the event will also be available, and an archive will be posted on the company's Investor Relations website within 24 hours of the live event.
Dyadic encourages questions to be submitted in advance via email, demonstrating its commitment to transparency and stakeholder engagement.
The company also included a safe harbor statement, cautioning that forward-looking statements regarding its strategies, expectations, and future performance are subject to risks that could cause actual results to differ from forecasts. Risks can include those outlined in Dyadic's recent SEC filings.
For further details, interested parties can consult the company’s website at www.dyadic.com or contact Chief Financial Officer Ping Rawson directly via phone or email.
This upcoming financial report and conference call represent a crucial opportunity for Dyadic to update stakeholders on its progress and financial health as it continues to innovate in the biotechnology sector.
MWN-AI** Analysis
As Dyadic International, Inc. prepares to release its full year financial results for 2025 on March 25, 2026, investors should focus on several key aspects that could influence the company's stock performance in the near term.
Dyadic's proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, represent significant potential for scalability in the production of high-value proteins across various industries. This unique competitive advantage positions Dyadic well within the biotech sector, particularly as demand for efficient protein production continues to rise in life sciences and food technology. Investors should closely analyze the company's performance in terms of revenue growth and partnerships as indicators of market traction.
The results on March 25 will likely provide insights into the company's revenue mix, typically comprising licensing revenue, collaboration income, and product sales. Analysts should scrutinize these segments to gauge the effectiveness of Dyadic's partnerships and the uptake of its platforms among key customers. A noticeable increase in licensing deals or new strategic partnerships could signal robust future growth and enhance investor confidence.
Furthermore, market sentiment will be shaped by Dyadic's commentary during the conference call regarding its pipeline advancements, ongoing clinical trials, and R&D investments. Clear and positive statements regarding future prospects could attract investors looking for growth opportunities in a sector often characterized by high volatility and risk.
Given Dyadic's current positioning and the ongoing evolution of biotechnological applications, it may be prudent for investors to closely monitor stock activity leading up to the earnings report. Any signs of speculative trading or significant movements in share price could suggest market expectations and potential reactions to the forthcoming financial disclosures. Overall, a balanced view incorporating both the risks highlighted in the safe harbor statements and the opportunities in Dyadic's innovative developments will be crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026.
Conference Call Information
Date: Wednesday, March 25, 2026
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID: 13758915
Webcast Link:. https://event.choruscall.com/mediaframe/webcast.html?webcastid=KTBXw5BI. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.
Contact:
Ping Rawson
Dyadic Applied BioSolutions
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ**
What are Dyadic International Inc. DYAI's expectations for revenue growth and profitability in 2026 following the financial results announcement on March 25, 2026?
Can Dyadic International Inc. DYAI provide updates on any key partnerships or collaborations that could impact future performance during the upcoming conference call?
How does Dyadic International Inc. DYAI plan to utilize its proprietary gene expression platforms to enhance its market position in the life sciences and industrial biotechnology sectors?
What risks does Dyadic International Inc. DYAI foresee that could affect its financial performance, as highlighted in its recent SEC filings?
**MWN-AI FAQ is based on asking OpenAI questions about Dyadic International Inc. (NASDAQ: DYAI).
NASDAQ: DYAI
DYAI Trading
3.75% G/L:
$0.799 Last:
6,673 Volume:
$0.775 Open:
